FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo for Treatment of ESR1-mutated Advanced Breast Cancer

  • This marks the second FDA-approved indication for Guardant360 CDx as a companion diagnostic in breast cancer treatment
  • ESR1 mutations are present in 40% of HR+, HER2- advanced breast cancers

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Guardant360 ® CDx as a companion diagnostic to identify advanced breast cancer patients with ESR1 mutations who may benefit from Eli Lilly and Company's Inluriyo (imlunestrant). Guardant360 CDx was approved in conjunction with Inluriyo for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1 -mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy (ET).

"This FDA approval provides another treatment for breast cancer patients with ESR1 mutations for their specific type of cancer along with expanded access to comprehensive genomic profiling with a simple blood draw," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "Precision testing plays a critical role in helping physicians identify the correct treatment, providing patients and their doctors with the comprehensive genomic profiling needed to see if they are eligible to receive the right treatment and improving outcomes."

Breast cancer remains the second leading cause of cancer death among women in the United States. 1 Guardant360 CDx was used to identify patients who had ESR1 mutations in the Phase 3 EMBER-3 trial, in which Inluriyo was found to reduce the risk of progression or death by 38% versus ET. 2 Patients with ESR1 E380, V422del, S463, L469, L536, Y537, and D538 mutations detected by Guardant360 CDx are eligible for treatment with Inluriyo.

The Inluriyo approval as a companion diagnostic marks the sixth CDx claim approved by the FDA for Guardant360 CDx, and the second FDA-approved indication in breast cancer treatment, following a similar approval for ORSERDU™ (elacestrant) granted by the FDA in 2023.

For more information about Inluriyo, please visit https://inluriyo.lilly.com/ .

About Guardant360 CDx

The first FDA-approved blood test for complete genomic testing, Guardant360 CDx is approved as a companion diagnostic for multiple therapies in non-small cell lung cancer. It is also the only FDA-approved companion diagnostic for targeted therapy in advanced breast cancer patients with ESR1 mutations. The test is broadly covered by Medicare and commercial insurers, representing over 300 million lives. For more information, visit the Guardant360 CDx website.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn , X (Twitter) and Facebook .

Guardant Health Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.

1 https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html

2 tps://investor.lilly.com/news-releases/news-release-details/us-fda-approves-inluriyo-imlunestrant-adults-er-her2-esr1

Investor Contact:
Zarak Khurshid
investors@guardanthealth.com

Media Contact:
Meaghan Smith
press@guardanthealth.com

News Provided by Business Wire via QuoteMedia

GH
The Conversation (0)
Admission to Trading on the Ghana Stock Exchange

Admission to Trading on the Ghana Stock Exchange

Atlantic Lithium to commence trading on the Main Market of the GSE on Monday, 13 May 2024

Atlantic Lithium Limited (AIM: ALL, ASX: A11, OTCQX: ALLIF, “Atlantic Lithium” or the “Company”), the African-focused lithium exploration and development company targeting to deliver Ghana’s first lithium mine, is pleased to announce that admission of its entire issued share capital (“Admission”), being 649,669,053 ordinary shares ("Ordinary Shares"), by introduction on the Main Market of the Ghana Stock Exchange (“GSE”) and commencement of trading of the Ordinary Shares will take place at 10:00 a.m. GMT on Monday, 13 May 2024, under the ticker “ALLGH”.

Keep reading...Show less
Benton and Sokoman Announce Updates on Newfoundland Joint Venture Projects Golden Hope and Grey River

Benton and Sokoman Announce Updates on Newfoundland Joint Venture Projects Golden Hope and Grey River

Additional High-Grade Cesium Assays from Hydra Dyke at Golden Hope: Gold Mineralization Expanded at Grey River

Benton Resources Inc. (TSXV: BEX) ("Benton") and Sokoman Minerals Corp. (TSXV: SIC) (OTCQB: SICNF) ("Sokoman") together, (the "Alliance") are pleased to report final assay results from the recently discovered cesium-rich dyke ("Hydra Dyke" or "Hydra") on the Golden Hope Joint Venture Project, as well as final drill results from a successful Phase 2 drilling campaign at Grey River; both projects are located in southwestern Newfoundland.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Benton Resources and Sokoman Minerals Report Kraken Lithium Prospect Phase 3 Drilling Program Underway; First Three Holes Cut Spodumene-Rich Dykes up to 14 m Thick

Benton Resources and Sokoman Minerals Report Kraken Lithium Prospect Phase 3 Drilling Program Underway; First Three Holes Cut Spodumene-Rich Dykes up to 14 m Thick

Benton Resources Inc. (TSXV: BEX) ("Benton") and Sokoman Minerals Corp. (TSXV: SIC) (OTCQB: SICNF) ("Sokoman"), together, (the "Alliance") are happy to report the commencement of the third phase of drilling at the Kraken Lithium Prospect. The Alliance is also extremely pleased to announce a new discovery, the Killick Zone, where surface grab samples graded up to 1.12% Li2O, located 200 m south of the East Dyke Zone (see press release October 18, 2022).

Currently, the Alliance has completed three holes GH-22-25, GH-22-26, and GH-22-27 on the new discovery, intersecting multiple, near-surface, spodumene-bearing dykes. Hole GH-22-25 cut eight pegmatite dykes ranging from 0.8 m to 11.2 m thick (drilled thickness, true thickness uncertain at this time), including an 8.8 m interval with visible spodumene in the 11.2 m dyke. Hole GH-22-26, drilled 35 m behind GH-22-25, also cut multiple spodumene-bearing dykes with drilled thicknesses ranging from 0.8 m to 10.5 m. The 10.5 m-thick dyke carried visible spodumene over its entire width. Hole GH-22-27 was drilled 30 m north of holes 25 and 26 along strike and cut two pegmatite dyke zones of 14.2 m and 2.95 m thick. Visual spodumene is present over 12.83 m of the 14.2 m interval and the entire length of the 2.95 m interval.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News